ECOG-ACRIN EA5162

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

For more information about this clinical trial, click here

Schema & Eligibility ECOG-ACRIN EA5162

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
OSF Saint Anthony Health Center, Alton, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Fort Smith, AK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO
Central Care Cancer Center, Bolivar, MO
Central Care Cancer Center, Great Bend, KS
Central Care Cancer Center, Garden City, KS

Ask your physician about participating in this clinical trial or call us.